scPharmaceuticals, Inc.

Actuate Therapeutics, Inc. grossed $22.4m from its initial public offering of 2.8 million shares priced at $8 each in the 15th biopharmaceutical company IPO in the US in 2024. It was not the smallest

The US FDA issued decisions on two new drug applications combining an on-body infusion device and an established drug last week. While the decisions went different ways – Supernus Pharmaceuticals, In

Prime Medicine, Inc. ’s $175m initial public offering late on 19 October was only the second IPO in the US launched by a biopharmaceutical firm during the second half of 2022 that raised more than $10

The US FDA’s user fee goal date calendar for October 2022 is slim, with only two novel agents, AstraZeneca PLC ’s immuno-oncologic tremelimumab and Amicus Therapeutics, Inc. ’ Pompe disease combo AT